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CD4 recovery following antiretroviral treatment
interruptions in children and adolescents with HIV infection
in Europe and Thailand
The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord,*
Objectives
The aim of the study was to explore factors associated with CD4 percentage (CD4%) reconstitution
following treatment interruptions (TIs) of antiretroviral therapy (ART).
Methods
Data from paediatric HIV-infected cohorts across 17 countries in Europe and Thailand were pooled.
Children on combination ART (cART; at least three drugs from at least two classes) for > 6 months
before TI of ≥ 30 days while aged < 18 years were included. CD4% at restart of ART (r-ART) and in the
long term (up to 24 months after r-ART) following the first TI was modelled using asymptotic regression.
Results
In 779 children with at least one TI, the median age at first TI was 10.1 [interquartile range (IQR)
6.4, 13.6] years and the mean CD4% was 27.3% [standard deviation (SD) 11.0%]; the median TI
duration was 9.0 (IQR 3.5, 22.5) months. In regression analysis, the mean CD4% was 19.2% [95%
confidence interval (CI) 18.3, 20.1%] at r-ART, and 27.1% (26.2, 27.9%) in the long term, with half
this increase in the first 6 months. r-ART and long-term CD4% values were highest in female
patients and in children aged < 3 years at the start of TI. Long-term CD4% was highest in those
with a TI lasting 1 to <3 months, those with r-ART after year 2000 and those with a CD4% nadir
≥ 25% (all P < 0.001). The effect of CD4% nadir during the TI differed significantly (P = 0.038) by
viral suppression at the start of the TI; in children with CD4% nadir < 15% during TI, recovery
was better in those virally suppressed prior to the TI; viral suppression was not associated with
recovery in children with CD4% nadir ≥ 25%.
Conclusions
After restart of ART following TI, most children reconstituted well immunologically. Nevertheless,
several factors predicted better immunological reconstitution, including younger age and higher
nadir CD4% during TI.
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Introduction
Life-long antiretroviral treatment (ART) is presently recom-
mended in patients with HIV infection, and long-term
adherence is often compromised by pill burden, toxicity and
interference with everyday life, particularly in adolescents
[1]. Consequently, randomized trials on the safety of
planned treatment interruptions (TIs) in adults and children
with HIV infection have been undertaken. Several studies
have clearly shown a detrimental effect of TIs in adults, with
patients experiencing a greater incidence of infections and
higher mortality rates on recommencement of ART, com-
pared with those on continuous ART [2–7]. TIs are therefore
not recommended in adult treatment guidelines.
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ORIGINAL RESEARCH
Only two trials have evaluated the consequences of
planned TIs in children. The first, Paediatric European Net-
work for Treatment of AIDS (PENTA) 11, was a randomized
trial of continuous ART compared with CD4-guided planned
TIs in children with suppressed viral load and good
immunological status at enrolment [8]. The second, the Chil-
dren with HIV Early Antiretroviral (CHER) randomized trial,
compared outcomes in children in whom ART was deferred
to those in children who were treated early but then com-
menced TIs at 1 or 2 years of age [9]. Both studies reported
no serious clinical or immunological outcomes during TIs.
Additionally, PENTA 11 showed increased CD4 cell recovery
after ART restart in younger children, while adult trials
reported no age effect [10]. These two paediatric trials sug-
gest that TIs may be more suitable for children than adults,
possibly as children experience a different immunological
course of HIV infection from adults. In the first years of life,
children experience moderate immunosuppression, but fol-
lowing ART initiation their immune reconstitution is stron-
ger than in adults [11,12] as a consequence of different
immunological kinetics as a result of functional thymus
activity in children [13].
Unplanned TIs continue to occur in routine clinical
practice, often because of a patient’s decision to stop
treatment or poor adherence, suggesting that the virologi-
cal and immunological status of patients at the point of
unplanned interruptions may be poorer than those in
experimental trials. In France, the risk of TIs of
≥ 3 months’ duration among 483 children was 7% after
1 year of ART, rising to 30% at 5 years [14]. Children
were matched to a control group who did not interrupt
treatment using age at start of TI. During follow-up, sev-
ere immunosuppression, defined as CD4 percentage
(CD4%) < 15%, occurred earlier in those who had a TI
than in the control sample. Four years after the TI, 53%
of children who had been back on ART for ≥ 6 months
had a CD4% > 25% compared with 74% in the continu-
ous ART group. However, there was no difference in
AIDS-free survival. In a second study from the USA
which examined the impact of unplanned TIs in 405 chil-
dren, of whom 17% had a TI, the largest declines in CD4
off ART occurred in those who had experienced the lar-
gest gains while on treatment pre-TI, but CD4 recovery
after ART restart was not investigated [15].
Here, we describe immunological outcomes of TIs in a
large collaboration of paediatric cohorts from 17 coun-
tries in Europe and Thailand. We hypothesized that char-
acteristics before and during the TI, in particular age and
nadir CD4%, would be associated with immunological
recovery following TI. Identification of children and ado-
lescents at risk of poor recovery is important to ensure
that treatment is restarted in a timely manner for those
most at risk. Our aim was therefore to investigate factors
that might predict improved immunological recovery
after ART restart.
Methods
Nineteen cohorts from 17 countries in the European Preg-
nancy and Paediatric HIV Cohort Collaboration (EPPICC)
contributed patient-level data. Anonymized demographic,
clinical, laboratory and treatment-related data were pro-
vided, following a standard operating procedure, and
merged using a modified HIV Cohorts Data Exchange
Protocol (http://www.hicdep.org) [16]. All cohorts had
local ethics approval to transfer anonymized data for this
study.
Children were included in this analysis if they were on
a combination ART (cART) regimen, defined as at least
three drugs from at least two classes or three nucleoside
reverse transcriptase inhibitors (NRTIs), for ≥ 6 months
before a TI. TIs were defined as a period off treatment of
≥ 30 days which commenced while < 18 years of age.
Subsequent TIs were defined as further interruptions of
≥ 30 days where the previous TI had ended ≥ 30 days
previously. Where there were < 30 days between two TIs
of ≥ 30 days, the time between the start of the first TI
and the end of the subsequent TI was considered as a sin-
gle TI. Children were excluded if they had participated in
TI trials, were followed up for < 30 days following restart
of ART after the first TI, or had no CD4% measurements
in the 24 months after restart of ART (or before the start
of the second TI, if within 24 months).
Statistical analysis
Characteristics of children at ART initiation and first TI
were described. CD4% response following restart of ART
up to 24 months after the first TI was modelled using
nonlinear asymptotic mixed effects models, with all
CD4% measurements in this period included with the
exception of those occurring after the start of a subse-
quent TI. Such models have previously been shown to
describe CD4 response after ART initiation well [17–19].
The model is parameterized in terms of an intercept
(inti), representing CD4% at restart of ART, an asymptote
(asyi), representing the longer term, stable CD4%, and a
rate parameter (ci), which represents the speed at which
change in CD4% occurs. CD4% for child i at time t is
described by CD4%ij ¼ asyi  ðasyi  intiÞecitij þ eij where
eij is the residual error. The change parameter c can be
used to calculate the time for half the CD4% recovery (i.e.
time to half the difference between the intercept and
asymptote) to take place as: In(2)/c.
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In univariable models, the unadjusted associations
between the intercept, asymptote and rate of change, c,
and a number of factors were explored. These included
sex and age (0 to < 3, 3 to < 6, 6 to < 11 or ≥ 11 years)
at each of the following time-points: (1) initiation of any
ART (not necessarily cART), (2) initiation of first cART,
(3) start of first TI and (4) first restart of ART. The effects
of being treatment na€ıve versus experienced at initiation
of the first cART regimen; not being seen in the clinic
versus being seen during the TI; the length of the TI (1 to
< 3, 3 to < 6, 6 to < 24 or ≥ 24 months); the calendar
year of the first ART restart (< 2000, 2000–2004, 2005–
2009 or ≥ 2010); starting versus not starting a new class
of drug at restart; and having planned versus unplanned
TI were explored. Planned TI was defined as stopping
ART because of the physician’s decision (for reasons
other than treatment/virological failure), noncompliance
or side effects/toxicity. Viral load (< 400 or ≥ 400 HIV-1
RNA copies/mL) at the start of the TI; nadir CD4%
(< 15%, 15 to < 25% or ≥ 25%) (1) prior to any ART, (2)
before initiation of the first cART and (3) during the first
TI; CD4% at the start of the first TI and mean CD4% dur-
ing the first TI were also considered.
With the exception of age at ART initiation, age at first
restart of ART (to avoid issues of multicollinearity), viral
load and CD4% before and during TI, any variables that
were significant at the 0.1 level in univariable analysis
were considered for inclusion in the first multivariable
model. A forward selection procedure was used to build
the model with the variables added one at a time to
either the intercept, asymptote or c, with entry probabil-
ity = 0.1.
A second multivariable model was then fitted, in
the subset of children with CD4% and viral load data
available, which included all variables in the first
model along with nadir CD4% prior to initiation of
the first cART, nadir CD4% during TI and viral load
at the start of TI. CD4% at the start of TI was not
included as it is highly correlated with nadir CD4%
during the TI; nadir CD4% during the TI was felt to
be more clinically useful to a physician potentially
faced with a decision regarding when to restart treat-
ment. Interactions between nadir CD4%, viral load
suppression and age at TI were also explored and
included in the model where significant. In sensitivity
analyses, modelling was repeated in only those who
initiated ART on a cART regimen and again including
only TIs of ≥ 3 months.
Characteristics of children were described using STATA/IC
15.1 (StataCorp, College Station, TX, USA) and models
were fitted using the nlme package in R v3.3.2 [20].
Results
A total of 7358 children started ART, of whom 901 (12%)
had a TI. Of these 901, 122 were excluded [22 were trial par-
ticipants (12 in PENTA 11, nine in PENPACT1 and one in
both), 85 had no CD4% in 24 months after ART restart, and
15 had < 30 days of follow-up after the restart of ART],
leaving 779 included in this analysis (Fig. S1). Characteristics
of the 779 included children, along with 6457 who never
had a TI, are summarized in Table 1. The median duration of
follow-up after first ART initiation was 13.1 [interquartile
range (IQR) 9.6, 15.8] years and the median duration of fol-
low-up from restart of ART after the first TI was 4.6 (IQR 2.5,
7.5 years).
For children who had a TI, 31% had more than one,
with the first lasting a median of 9.0 (IQR 3.5, 22.5)
months and occurring at a median age of 10.1 (IQR 6.4,
13.6) years. Age at and duration of first and subsequent
TIs are summarized in the bottom half of Table 1 along
with ART regimens used before and after the first TI. All
subsequent results are based on the first TI only.
At the time of the first TI, 426 (55%) were taking a
protease inhibitor (PI) + NRTI regimen and 294 (38%)
were on a nonnucleoside reverse transcriptase inhibitor
(NNRTI) + NRTI regimen; the reason for the TI did not
differ significantly between patients on a PI and those on
an NNRTI (P = 0.082). Following the TI, 392 (50%)
restarted a regimen containing a different class of drug,
while 126 (16%) restarted on the pre-TI regimen. For the
remainder, 67 (9%) had a change in the backbone NRTIs
only and 194 (22%) changed drug within a class other
than NRTI. Those who were on an NNRTI prior to the TI
were significantly more likely to start a new class after
the TI (210 of 294; 71%) than those on PIs (173 of 426;
41%; P < 0.001). Three deaths occurred within 24 months
of restarting ART [one at 3 months in 2005 (invasive
bacterial infection), one at 4 months in 2000 (AIDS-
defining event; unspecified), and one at 15 months in
2008 (HIV-related)].
CD4% recovery after restarting ART
Median calendar year of ART restart after the first TI was
2006 (IQR 2003, 2009). At the start of the first TI, the
mean CD4% was 27% (SD 11%), which fell to a mean
nadir of 17% (SD 9%) during the TI. Half of the children
had a CD4% at the time of restart, for whom the mean
was 18% (SD 10%). A CD4% was available for 546 at 12
( 3) months after ART restart, at which point the mean
was 25% (SD 10%), and in 425 with a measurement at 24
( 3) months the mean was 27% (SD 10%). Observed
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CD4% values up to 24 months after restart of ART fol-
lowing first TI are presented in Figure 1. During this per-
iod, 4023 CD4% measurements were recorded with a
median of 5 (IQR 3, 7) measurements (range 1–22) per
child.
The overall estimated intercept was 19.2% (95% CI
18.3, 20.1%) and the asymptote was 27.1% (95% CI
26.2, 27.9%), indicating a modelled average CD4% of
19% at restart rising to 27% in the long term. The rate
parameter was estimated as 0.119 (95% CI 0.104,
0.133) which corresponds to a time of 6 months [ln
(2)/c = ln (2)/0.119 = 5.8 months] for half the CD4%
recovery to take place. Univariable associations between
demographic and treatment characteristics and CD4%
up to 24 months following restart of ART are shown in
Table 2.
In the first multivariable model, including all children
but not laboratory data (Table 3), female sex and younger
age at first TI were independent predictors of higher
CD4% at restart (intercept) and in the long term (asymp-
tote). Estimated mean CD4% values after ART restart for
male and female patients of different ages are shown in
Figure 2. Earlier year of first restart of ART and TI length
of 3 to <6 months were also associated with lower long-
term CD4%. None of the variables were associated with
the rate of recovery (C).
The second multivariable model included 365 children
with nadir CD4% prior to first cART, nadir CD4% during
TI and viral load at the start of TI. These children were
more likely to be from the UK/Ireland (45% versus 24%
or those with incomplete data) and to have a longer TI
[median 11.9 (IQR 5.1, 27.6) versus 5.6 (IQR 2.6,
17.0) months for those with incomplete data] but did not
Table 1 Characteristics of children who did and did not interrupt
treatment
Interrupted
treatment
Did not
interrupt
treatment
n (%) or
median (IQR)
All 779 6457
Female gender 414 (53) 3307 (51)
Perinatally acquired infection 723 (93) 5730 (89)
Cohort
UK and Ireland 264 (34) 1267 (20)
Italy 134 (17) 1261 (20)
France 131 (17) 443 (7)
Spain 95 (12) 754 (12)
Romania 38 (5) 418 (6)
Thailand 38 (5) 809 (12)
Other* 79 (10) 1505 (23)
Age at ART initiation (years) 2.5 (0.5, 6.4) 4.2 (1.0, 8.7)
Age at cART initiation (years) 5.3 (2.1, 8.7) 6.3
(2.2, 10.4)
Initiated ART on cART 374 (48) 3979 (62)
Initial cART regiment
PI + NRTI 433 (56) 2587 (44)
NNRTI + NRTI 260 (33) 2614 (40)
NRTI only 55 (7) 213 (3)
PI + NNRTI 31 (4) 139 (2)
Other 0 6 (0)
No cART regimen initiated 0 628 (10)
Calendar year of first
cART regiment
1999 (1998, 2003) 2004 (2000, 2007)
Nadir CD4% prior to any ART initiation
< 15% 203 (35) 1996 (42)
15–24% 171 (30) 1532 (32)
≥ 25% 200 (35) 1257 (26)
Missing 205 (26) 1672 (26)
Number of TIs
1 540 (69)
2 168 (22)
3 53 (7)
≥ 4 18 (2)
Age at start of TI (years)
1st IT 10.1 (6.4, 13.6)
2nd TI 13.8 (9.9, 15.9)
3rd TI 14.8 (10.8, 16.0)
4th TI 15.8 (14.1, 16.9)
Duration of TI (months)
1st IT 9.0 (3.5, 22.5)
2nd TI 6.7 (3.0, 12.5)
3rd TI 5.5 (3.0, 8.5)
4th TI 3.9 (3.0, 7.8)
Reason for first TI
Patient decision/noncompliance 280 (49)
Treatment failure 126 (22)
Physicians decision 95 (17)
Side effects/toxicity 53 (9)
Other 21 (4)
Missing 204 (26)
Regimen immediately prior to first TI
PI + NRTI 426 (55)
NNRTI + NRTI 294 (38)
PI + NNRTI + NRTI 59 (8)
Regimen at restart following first TI
PI + NRTI 456 (60)
NNRTI + NRTI 165 (21)
Table 1 (Continued )
Interrupted
treatment
Did not
interrupt
treatment
n (%) or
median (IQR)
3 NRTIs 72 (9)
PI + NNRTI + NRTI 86 (11)
Restarted on a different
class after TI
392 (50)
ART, antiretroviral therapy; cART, combination antiretroviral therapy;
IQR, interquartile range; PI, protease inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhi-
bitor; TI, treatment interruption.
*Other cohorts contributing < 5% of patients with TI were from
Switzerland (n = 23 with TI, 129 without), Belgium (n = 17 with TI, 115
without), the Netherlands (n = 14 with TI, 259 without), Russia (n = 10
with TI, 149 without), Portugal (n = 5 with TI, 46 without), Sweden
(n = 4 with TI, 88 without), Ukraine (n = 4 with TI, 622 without) and
Poland (n = 2 with TI, 57 without). Additionally, Greece and Germany
each had 20 children without TIs and none with.
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differ by other characteristics listed in Table 1. In this
model (Table 3), the only factors from model 1 to remain
significant were the effects of year of ART restart, age at
TI and length of TI on the long-term CD4%. The higher
long-term CD4% in younger children implies better
CD4% recovery compared with older children who
restarted ART with a similar CD4%. Conversely, the lack
of difference between male and female patients suggests
that, after adjusting for higher average CD4% in female
individuals, there was no difference in the rate of recov-
ery between the sexes.
Lower CD4% nadir prior to cART was associated with
lower CD4% at restart only. Lower CD4% nadir during
the TI was also associated with lower CD4% at restart, as
well as lower long-term CD4%. However, there was a sta-
tistically significant interaction between CD4% nadir dur-
ing the TI and viral suppression prior to the TI
(P = 0.038) and consequently the magnitude of the
long-term effect of nadir CD4% during the TI differed by
viral load suppression at TI start (Fig. 3). In children with
CD4% nadir < 15% during the TI, those who had an
undetectable viral load at the start of the TI reached a
higher long-term CD4% than those without suppression
(Fig. 3a and b); viral suppression was not associated with
recovery in those with CD4% nadir ≥ 25% (Fig. 2e and f).
Two hundred and sixty-two children included in the
model had a CD4% available prior to the TI (< 2 months
prior to stopping treatment). Predicted long-term CD4%
was highly correlated with pre-TI CD4% (r = 0.63;
P < 0.001; Fig. S2).
In a sensitivity analysis which included 374 children
who were treatment na€ıve at cART start (Table S1), and
675 who had a TI of ≥ 3 months (Tables S2 and S3),
results were broadly similar to those of the first and sec-
ond models.
Discussion
ART interruptions occurred in just over 1 in 10 children
and adolescents living with HIV. In our large data set
from several cohorts in Europe and Thailand, we found
that 12% of children who started ART had a TI. The first
TI occurred at an average age of 10 years after 5.5 years
on cART, with 21% having a further TI. This proportion
of children with a TI is lower than that reported in a
French cohort (42%) [14] and in a US cohort (18%) in
2008 [15]. Duration of TIs varied from a median of
9 months in our study, to 12 months in the French study
and 14 months in the US study. Moreover, TIs occurred
at a median age of 10.1 versus 8 years in the French
cohort and 12.8 years in the US cohort. Detailed compar-
isons among studies are difficult and differences in defi-
nitions of TI (we defined a TI as a 1-month interruption,
while the other studies defined it as a 3-month interrup-
tion), availability of treatment and calendar period of
enrolment may explain differences in the proportions
0
–12 –6 0
Time since restart of ART (months)
During treatment
interruption
After restart of ART
6 12 18 24
20
40
60
C
D
4%
Fig. 1 Observed CD4 percentage (CD4%) during first treatment interruption (TI) and in the 24 months following restart of antiretroviral ther-
apy (ART).
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Table 2 Univariable associations between patient characteristics and CD4 percentage (CD4%) at restart of antiretroviral therapy (ART)
(intercept) and up to 24 months after restart of ART (asymptote), and speed of recovery (C) following first treatment interruption (TI)
n (%)
Intercept (CD4% at restart) Asymptote (long-term CD4%) C (speed of recovery)
b (95% CI) P-value b (95% CI) P-value b (95% CI) P-value
Sex
Male 365 (47) Ref Ref Ref
Female 414 (53) 3.8 (2.0, 5.6) < 0.001 4.23 (2.52, 5.93) < 0.001 0.002 (0.032, 0.028) 0.892
Age at ART initiation
0 to < 3 years 415 (53) Ref Ref Ref
3 to < 6 years 151 (19) 2.7 (5.1, 0.4) < 0.001 4.9 (7.1, 2.7) < 0.001 0.019 (0.024, 0.063) 0.678
6 to < 11 years 154 (20) 4.3 (6.6, 2.0) 5.4 (7.6, 3.2) 0.021 (0.019, 0.061)
≥ 11 years 59 (8) 6.0 (9.4, 2.6) 9.0 (12.3, 5.6) 0.006 (0.059, 0.071)
Initiated ART on cART
No 405 (52) Ref Ref Ref
Yes 374 (48) 0.0 (1.8, 1.8) 0.994 0.3 (1.5, 2.0) 0.762 0.007 (0.023, 0.037) 0.631
Age at cART initiation
0 to < 3 years 243 (31) Ref Ref Ref
3 to < 6 years 192 (25) 3.6 (6.0, 1.3) < 0.001 5.2 (7.4, 3.0) < 0.001 0.004 (0.042, 0.034) 0.813
6 to < 11 years 247 (33) 5.7 (7.9, 3.5) 7.3 (9.4, 5.2) 0.011 (0.025, 0.047)
≥ 11 years 97 (13) 7.3 (10.2, 4.3) 10.6 (13.5, 7.8) 0.019 (0.041, 0.137)
Age at first TI
0 to < 3 years 63 (8) Ref Ref Ref
3 to < 6 years 113 (15) 3.9 (7.7, 0.0) < 0.001 4.7 (8.3, 1.1) < 0.001 0.045 (0.010, 0.100) 0.120
6 to < 11 years 259 (33) 5.7 (9.09, 2.4) 5.9 (9.2, 2.6) 0.007 (0.034, 0.049)
≥ 11 years 344 (44) 8.1 (11.4, 4.9) 11.6 (14.8, 8.4) 0.039 (0.005, 0.083)
Age at first restart of ART
0 to < 3 years 33 (4) Ref Ref Ref
3 to < 6 years 82 (11) 1.0 (5.8, 3.9) < 0.001 2.2 (7.0, 2.6) < 0.001 0.023 (0.040, 0.087) 0.612
6 to < 11 years 212 (27) 6.6 (11.0, 2.2) 5.2 (9.6, 0.8) 0.022 (0.030, 0.075)
≥ 11 years 452 (58) 8.1 (12.3, 3.9) 9.4 (13.6, 5.2) 0.034 (0.017, 0.0.84)
Missing during first TI
No 435 (56) Ref Ref Ref
Yes 344 (44) 3.3 (1.2, 5.5) 0.003 5.2 (7.5, 2.8) < 0.001 0.247 (0.297, 0.197) < 0.001
Length of TI
1 to < 3 months 160 (21) Ref Ref Ref
≥ 3 to < 6 months 156 (20) 0.2 (3.6, 2.1) 0.293 3.2 (5.8, 0.5) < 0.001 0.001 (0.052, 0.054) 0.995
≥ 6 to < 24 months 283 (36) 2.5 (5.0, 0.0) 1.6 (4.0, 0.7) 0.004 (0.042, 0.034)
≥ 24 months 180 (23) 1.2 (3.9, 1.5) 1.2 (1.5, 3.8) 0.004 (0.046, 0.038)
Year of first restart of ART
< 2000 39 (5) 1.4 (2.8, 5.6) 3.3 (7.3, 0.6) 0.010 (0.069, 0.049)
2000–2004 248 (32) Ref 0.033 Ref 0.014 Ref 0.990
2005–2009 336 (43) 0.6 (2.7, 1.5) 0.4 (2.4, 1.6) 0.001 (0.036, 0.033)
≥ 2010 156 (20) 3.5 (1.0, 6.1) 2.3 (0.2, 4.8) 0.003 (0.049, 0.044)
Started new class at ART restart
No 387 (50) Ref Ref Ref
Yes 392 (50) 2.5 (4.6, 0.7) 0.043 0.1 (1.8, 1.7) 0.652 0.001 (0.022, 0.041) 0.556
Planned TI* (missing: n = 204)
No 427 (74) Ref Ref Ref
Yes 148 (26) 1.6 (0.7, 3.9) 0.158 2.6 (0.2, 5.0) 0.006 0.014 (0.052, 0.242) 0.479
Viral load
At first TI (missing: n = 283)
HIV RNA ≥ 400 copies/mL 363 (73) Ref Ref Ref
HIV RNA < 400 copies/mL 133 (27) 3.6 (1.2, 6.0) 0.003 4.7 (2.5, 6.9) < 0.001 0.053 (0.002, 0.104) 0.043
Nadir CD4%
Prior to ART initiation (missing: n = 205)
< 15% 203 (35) Ref Ref Ref
≥ 15 to < 25% 171 (30) 4.8 (2.3, 7.3) < 0.001 4.5 (2.2, 6.9) < 0.001 0.014 (0.035, 0.063) 0.323
≥ 25% 200 (35) 8.7 (6.3, 11.0) 7.9 (5.6, 10.2) 0.023 (0.065, 0.020)
Prior to cART initiation (missing: n = 149)
< 15% 306 (49) Ref Ref Ref
≥ 15 to < 25% 184 (29) 7.3 (5.2, 9.5) < 0.001 5.6 (3.5, 7.7) < 0.001 0.003 (0.045, 0.038) 0.969
≥ 25% 140 (22) 12.3 (9.9, 14.6) 9.4 (7.2, 11.7) 0.004 (0.044, 0.052)
During first TI (missing: n = 141)
< 15% 288 (45) Ref Ref Ref
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with TIs. For example, in this study and the French
cohort, the risk of TI was highest in those initiating ART
before 2000, with 51% of the French cohort starting
cART in this period [14] compared to only 27% of
EPPICC. Further, in the French cohort the median age at
TI was 5.8 years in those interrupting treatment from
1996 to 1999, rising to 13.6 years in 2005–2010 [14],
suggesting that newer ART regimens are more tolerable
and consequently TIs are occurring later and less often.
However, the main message is that TIs are relatively com-
mon, occur mainly in the pre-adolescent or adolescent
age group, and can last for a long period, often 1 year or
more.
In our study, the most frequent reason for a TI (in
about half of the cases known) was the patient’s decision/
noncompliance, and this is consistent with the occurrence
of most TIs in the pre-adolescent and adolescent age
range. In the subgroup who had more than one TI, the
second, third and fourth TIs, respectively, occurred at
13.8, 14.8 and 15.8 years of age, reflecting the instability
of ART adherence during adolescence. Only a quarter of
TIs were attributable to treatment failure, 17% depended
on the physician’s decision and 9% were because of toxi-
city and side effects. Type of regimen, in particular PI-
based versus NNRTI-based, was not associated with the
reason for the TI. This suggests that treatment type was
not a main reason for stopping treatment. Nevertheless,
children on NNRTI-based regimens at TI were much more
likely to switch to a new class of drug at restart com-
pared with those on PI-based regimens (71% versus 41%,
respectively). Switch to a different type of regimen was
associated with higher CD4% at restart, but switching had
no long-term effect.
At the first TI, children had relatively good immuno-
logical status (mean CD4% value 27.3%), although most
lacked virological control [27% had a suppressed viral
load (< 400 copies/mL)]. This is in line with the main
reasons for TIs, confirming that the children and ado-
lescents represent a group of patients who have low/ir-
regular adherence, recent ART-related side effects/
toxicity or treatment failure. At the end of the TI, the
mean CD4% had fallen to 19%, rising to 27% by
2 years after the end of the TI and therefore slowly
returning to pre-TI values. This may be reassuring in
terms of the safety of TIs in children, as also suggested
by planned interruption studies such as the extension
study in the PENTA 11 trial [10] and the latest results
from the CHER trial, which showed that long-term
CD4-for-age recovery was equivalent to children’s pre-
interruption steady state [9]. Results from both trials
are potential indicators that in childhood TIs could be
a safe option with regular CD4 monitoring, even if not
routinely recommendable. Moreover, authors from the
CHER trial suggested that in children a preserved CD4
set-point exists which depends on thymic output and
na€ıve CD4 T-cell dynamics. However, our results from
a real-world setting suggest caution as several factors
were found in multivariable analysis to influence long-
term recovery after TI.
Age at TI was found to be associated with level of
CD4% recovery, with the highest CD4% at restart and in
the long term seen in the younger children aged
< 3 years at the first TI. Furthermore, when we adjusted
for CD4% during TI, CD4% recovery was highest in the
youngest children, suggesting less ability to reconstitute
CD4 cells with increasing age. This finding reinforces a
Table 2 (Continued )
n (%)
Intercept (CD4% at restart) Asymptote (long-term CD4%) C (speed of recovery)
b (95% CI) P-value b (95% CI) P-value b (95% CI) P-value
≥ 15 to < 25% 232 (36) 10.8 (9.3, 12.4) < 0.001 6.8 (4.9, 8.7) < 0.001 0.006 (0.039, 0.027) 0.021
≥ 25% 118 (19) 21.0 (18.8, 23.2) 12.4 (10.3, 14.7) 0.138 (0.038, 0.267)
CD4%
At start of first TI (missing: n = 386)
< 15% 53 (14) Ref Ref Ref
≥ 15 to < 25% 105 (27) 9.5 (5.9, 13.1) < 0.001 5.5 (2.1, 8.9) < 0.001 0.059 (0.114, 0.004) 0.084
≥ 25% 235 (60) 17.9 (14.6, 21.2) 13.5 (10.5, 16.5) 0.046 (0.094, 0.002)
During first TI (mean) (missing: n = 141)
< 15% 173 (27) Ref Ref Ref
≥ 15 to < 25% 277 (43) 9.5 (7.7, 11.3) < 0.001 6.5 (4.5, 8.6) < 0.001 0.000 (0.032, 0.033) 0.995
≥ 25% 188 (30) 20.3 (18.4, 22.3) 14.6 (12.4, 16.8) 0.002 (0.043, 0.040)
Parameters estimated using multilevel asymptotic regression models. The intercept represents the CD4% at restart of ART, with b representing the dif-
ference in mean CD4% in patients with specific characteristics and the reference group. Similarly, the asymptote represents the longer term CD4% (up
to 24 months after restart) and b represents longer term differences in mean CD4%. C is a rate parameter; negative values indicate a slower increase
in CD4% and positive values indicate a faster increase. Time to half the total CD4% recovery can be estimated as In(2)/c.
cART, combination antiretroviral therapy; CI, confidence interval.
*Planned TI is defined as stopping ART because of physician’s decision or side effects/toxicity.
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Table 3 Multivariable associations between characteristics and CD4 percentage (CD4%) at antiretroviral therapy (ART) restart (intercept) and
in the 24 months after ART restart (asymptote) and speed of recovery (C) following the first treatment interruption (TI)
Intercept (CD4% at restart) Asymptote (long-term CD4%) C (speed of recovery)
b (95% CI) P-value b (95% CI) P-value b (95% CI) P-value
Model 1: excluding laboratory data (n = 799)
Constant 22.6 (19.5, 25.8) < 0.001 33.19 (30.0, 36.4) < 0.001 0.117 (0.103, 0.132) < 0.001
Sex
Male Ref < 0.001 Ref < 0.001
Female 3.7 (2.0, 5.4) 4.0 (2.5, 5.5)
Age at first TI
0 to < 3 years Ref < 0.001 Ref < 0.001
3 to < 6 years 2.7 (6.4, 1.0) 3.4 (6.0, 0.1)
6 to < 11 years 5.2 (8.4, 2.0) 5.7 (8.5, 2.8)
≥11 years 7.3 (10.5, 4.1) 10.7 (13.6, 7.8)
Length of TI
1 to < 3 months Ref 0.027
≥ 3 to < 6 months 2.7 (4.9, 0.4)
≥ 6 to < 24 months 1.3 (3.3, 0.7)
≥ 24 months 0.7 (3.0, 1.7)
Year of first restart of ART
2000–2004 5.8 (9.3, 2.4) < 0.001
< 2000 Ref
2005–2009 0.3 (1.5, 2.0)
≥ 2010 0.7 (1.5, 2.8)
Model 2: including laboratory data (n = 365)
Constant 10.6 (7.2, 14.0) < 0.001 25.9 (21.0, 30.8) < 0.001 0.127 (0.097, 0.157) < 0.001
Sex
Male Ref Ref
Female 0.7 (2.3, 0.9) 0.393 0.3 (1.6, 2.2) 0.739
Age at first TI
0 to < 3 years Ref 0.428 Ref < 0.001
3 to < 6 years 1.5 (2.0, 5.0) 0.6 (4.6, 3.5)
6 to < 11 years 0.7 (2.4, 3.9) 2.5 (6.2, 1.2)
≥ 11 years 0.1 (3.1, 3.3) 5.8 (9.5, 2.0)
Length of TI
1 to < 3 months Ref 0.047
≥ 3 to < 6 months 3.5 (7.0, 0.1)
≥ 6 to < 24 months 1.3 (4.3, 1.6)
≥ 24 months 1.6 (1.8, 4.9)
Year of first restart of ART
< 2000 6.9 (12.1, 1.8)
2000–2004 Ref 0.010
2005–2009 2.2 (4.5, 0.1)
≥ 2010 2.6 (5.4, 0.2)
VL at first TI
HIV RNA ≥ 400 copies/mL Ref 0.903 Ref 0.007 Ref 0.008
HIV RNA < 400 copies/mL 0.1 (2.1 to 1.9) 4.7 (1.3, 8.1) 0.076 (0.020, 0.131)
Nadir CD4% prior to cART initiation
< 15% Ref 0.002 Ref 0.747 Ref 0.900
≥ 15 to < 25% 3.8 (1.7, 5.8) 1.7 (0.7, 4.0) 0.002 (0.052, 0.057)
≥ 25% 3.9 (1.5, 6.3) 1.5 (1.2, 4.1) 0.019 (0.074, 0.036)
Nadir CD4% during first TI
< 15% Ref < 0.001 Ref < 0.001 Ref 0.004
≥ 15 to < 25% 9.2 (7.3, 11.1) 7.3 (4.7, 9.8) 0.005 (0.054, 0.044)
≥ 25% 17.8 (14.7, 21.0) 13.5 (10.0, 17.0) 0.338 (0.137, 0.539)
Interaction: VL at start of TI 9 CD4% nadir during TI
VL < 400 copies/mL and nadir CD4% ≥ 15 to < 25% 3.2 (7.9, 1.4) 0.038
VL < 400 copies/mL and nadir CD4% ≥ 25% 5.3 (10.6, 0.1)
Parameters were estimated using multilevel asymptotic regression models. The intercept represents the CD4% at restart of ART, with b representing
the difference in mean CD4% in patients with specific characteristics and the reference group. Similarly, the asymptote represents the longer term
CD4% (up to 24 months after restart) and b represents longer term differences in mean CD4%. C is a rate parameter; negative values indicate a
slower increase in CD4% and positive values indicate a faster increase. The intercept, asymptote and C constants represent the mean CD4% at restart
and in the long term and the rate parameter for patients in the reference groups. Time to half the total CD4% recovery can be estimated as In(2)/c.
CI, confidence interval; VL, viral load.
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general belief that children have major immunological
advantages as compared to adults after starting ART.
Indeed, younger children have been shown to produce a
stronger recovery and more na€ıve CD4 T cells when the
virus is suppressed as a consequence of persistence of
high levels of thymic activity [13]. Adolescents have
reduced thymic activity as compared with younger chil-
dren and therefore a worse immunological response when
resuming ART after TIs.
A very important issue is the safety of a TI in the first
years of life in children who have commenced ART at an
early age [21,22]. Findings from the CHER trial suggest the
feasibility of this strategy [9]. Our results also suggest that
good immunological recovery is possible in younger children
interrupting treatment, particularly before 3 years of age.
In our study, we found that female patients had a
CD4% on average 4% higher than that of male patients
of the same age, both at restart of ART and in the long
term. This is consistent with a study of pre-pubertal peri-
natally HIV-infected children which found lower HIV
RNA and high CD4 levels in girls, with girls having a
CD4% on average 3% higher than that of boys [23]. How-
ever, when we adjusted our model for CD4% nadir during
the TI and prior to ART, the gender differences
disappeared. This suggests that, while female individuals
have a higher CD4% than male individuals on average, in
male and female individuals with similar CD4% during
the TI (and therefore at restart), CD4% recovery occurs at
a similar rate.
We observed a high variability in the length of the TI,
with about half of children interrupting ART for > 1 year.
A mean 0.66% monthly decrease in CD4% during TIs
among children has been reported [24] and, as a conse-
quence, lower CD4% levels have been found in children
with longer TIs. However, we found some differences in
long-term CD4% by length of TI, but no difference in
CD4% at restart. This may suggest that the children, in
clinical practice, were advised to restart at similar CD4%
levels, independently of the length of the TI. Surprisingly,
we found that children who had a TI of 3 to < 6 months
had the lowest long-term CD4% level. This could suggest
that those children who restarted ART were the rapid pro-
gressors, who had a rapid CD4 decline following TI, when
compared to those who were able to remain off treatment
for longer periods. Early start of ART may have masked
the ‘individual’ immunological progression profiles [25]
observed as different patterns of progression (rapid pro-
gressors, low progressors and nonprogressors) in the
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Fig. 2 Estimated mean CD4 percentage (CD4%) after restart of antiretroviral therapy (ART) following first treatment interruption (TI) by sex
and age at start of first TI. Fitted values represent mean CD4% for a child restarting ART in 2010 or later following a TI of 6 to < 24 months
without adjustment for prior CD4% or viral load.
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natural history of paediatric HIV infection [26]. During the
Tis, the ‘individual’ patterns of progression may re-
emerge.
To explore the possible role of an individual ‘immuno-
logical profile’ in the CD4% slope during TI and after ART
restart, we included CD4% nadir prior to cART and during
TI in the analysis. We found a small effect of CD4% nadir
prior to cART on CD4% at restart but this disappeared in
the longer term in multivariable models. However, nadir
during TI was a significant predictor of CD4% both at
restart and in the longer term, with the biggest gains in
CD4% seen in those with the lowest values during TI, and
Fig. 3 Estimated mean CD4 percentage (CD4%) after restart of antiretroviral therapy (ART) following first treatment interruption (TI) by age,
viral load (VL) at start of TI, and CD4% nadir during TI. Fitted values represent mean CD4% for a male patient restarting ART in 2010 or later
following a TI of 6 to < 24 months who had a nadir CD4% of 15 to < 25% prior to initiation of first combination ART (cART).
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in particular in those who were virologically suppressed
prior to TI. In this subgroup of children with undetectable
viral load at the beginning of TI, the beneficial effect of
restarting ART could be much stronger in those children
who experienced more immunological deterioration during
TI, as children whose CD4% level drops the most have the
largest gain to make [26].
Our collaborative study has several limitations, partly
as a consequence of the multi-cohort, retrospective
source of our data set. Firstly, we had no data on
patients’ adherence to ART before and after TIs. Secondly,
we lacked data on functional aspects of immunological
deterioration, such as inflammatory biomarkers or
response to immunizations. Thirdly, data on clinical fea-
tures of HIV infection were available from few cohorts
and therefore were not included in the analysis. We also
lacked detailed information on reason for TI. Reasons for
stopping treatment reported to the participating cohorts
by clinics include treatment failure, toxicity and noncom-
pliance, as well as physician or patient decision. Physi-
cian’s decision is used only if it was a decision based on
a reason other than those listed above. We considered
interruptions resulting from reasons reported as physi-
cian’s decision as planned interruptions, but as no further
details are available these could not be confirmed.
Finally, cohorts included in the study range from having
national coverage to being hospital based and so results
may not be generalizable to children treated outside these
sites. However, there are also several strengths in the col-
laborative nature of the study, which provided a large
cohort of children and adolescents followed for many
years after starting ART, with regular CD4 monitoring.
The modelling made use of longitudinal CD4 measure-
ments, with results providing insight into outcomes asso-
ciated with TIs in a real-life setting. In this model, we
used CD4% as it was hypothesized that age would be a
strong predictor of CD4 recovery. While the majority of
children were > 6 years old when restarting ART, 15%
were aged < 6 years. The youngest children showed the
strongest CD4% response on restarting ART and the use
of CD4% rather than CD4 count allowed us to explore
age effects which could potentially have been masked by
natural decline had CD4 counts been used instead.
In conclusion, perinatally infected children are faced
with the prospect of lifelong ART, with a high probability
of accumulating side effects, metabolic toxicity, poor
compliance, attrition and increasing numbers of muta-
tions associated with ART resistance. Therefore, paediatric
HIV experts world-wide should continue their efforts to
determine whether the burden of ART can be reduced
during childhood and adolescence. Our real-world data
demonstrate that TIs continue to occur, particularly in
adolescents, and mainly as a result of their decision. Our
findings suggest that immunological recovery following a
TI is less efficient at older ages and in those children/
adolescents with low CD4% values during the TI. While
young children did show good potential for recovery, it
is important to monitor CD4 during any TI to ensure that
treatment is restarted prior to large declines in CD4 cell
count.
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G Koopmans, J. J. A van Kampen and S. D. Pas. Rad-
boudumc, Nijmegen: HIV treating physicians: S. S. V.
Henriet, M. van de Flier and K. van Aerde. HIV nurse
consultants: R. Strik-Albers. HIV clinical virologists/che-
mists: J. Rahamat-Langendoen and F. F. Stelma. Universi-
tair Medisch Centrum Groningen, Groningen: HIV
treating physician: E. H. Sch€olvinck. HIV nurse consul-
tant: H. de Groot-de Jonge. HIV clinical virologists/che-
mists: H. G. M. Niesters, C. C. van Leer-Buter and M.
Knoester. Wilhelmina Kinderziekenhuis, UMCU, Utrecht:
HIV treating physicians: L. J. Bont, S. P. M. Geelen and
T. F. W. Wolfs. HIV nurse consultant: N. Nauta. HIV clin-
ical virologists/chemists: C. W. Ang, R. van Houdt, A. M.
Pettersson and C. M. J. E. Vandenbroucke-Grauls.
Coordinating centre: Director: P. Reiss. Data analysis:
D. O. Bezemer, A. I. van Sighem, C. Smit, F. W. M. N. Wit
and T. S. Boender. Data management and quality control:
S. Zaheri, M. Hillebregt and A. de Jong. Data monitoring:
D. Bergsma, S. Grivell, A. Jansen, M. Raethkke and R.
Meijering. Data collection: L. de Groot, M. van den Akker,
Y. Bakker, E. Claessen, A. El Berkaoui, J. Koops, E. Krui-
jne, C. Lodewijk, L. Munjishvili, B. Peeck, C. Ree, R. Reg-
top, Y. Ruijs, T. Rutkens, M. Schoorl, A. Timmerman, E.
Tuijn, L. Veenenberg, S. van der Vliet, A. Wisse and T.
Woudstra. Patient registration: B. Tuk.
Poland: Polish paediatric cohort: Head of the team:
Prof Magdalena Marczynska. Members of the team:
Jolanta Popielska; Maria Pokorska-Spiewak; Agnieszka
Ołdakowska; Konrad Zawadka; Urszula Coupland. Admin-
istration assistant: Małgorzata Doroba, Medical University
of Warsaw, Poland, Department of Children’s Infectious
Diseases; Hospital of Infectious Diseases in Warsaw,
Poland.
Portugal: Centro Hospitalar do Porto: Laura Marques,
Carla Teixeira, Alexandre Fernandes. Hospital de Santa
Maria/CHLN: Filipa Prata.
Romania: ‘Victor Babes’ Hospital Cohort, Bucharest:
Luminita Ene.
Russia: Federal State-owned Institution ‘Republican
Clinical Infectious Diseases Hospital’ of the Ministry of
Health of the Russian Federation, St Petersburg: Liubov
Okhonskaia, Evgeny Voronin, Milana Miloenko and Svet-
lana Labutina.
Spain: CoRISPE-cat, Catalonia: financial support for
CoRISPE-cat was provided by the Instituto de Salud Car-
los III through the Red Tematica de Investigacion Cooper-
ativa en Sida. Members: Hospital Universitari Vall
d’Hebron, Barcelona [Pere Soler-Palacın, Maria Antoinette
Frick and Santiago Perez-Hoyos (statistician)], Hospital
Universitari del Mar, Barcelona (Antonio Mur and Nuria
Lopez), Hospital Universitari Germans Trias i Pujol, Bada-
lona (Marıa Mendez), Hospital Universitari JosepTrueta,
Girona (Lluıs Mayol), Hospital Universitari Arnau de Vila-
nova, Lleida (Teresa Vallmanya), Hospital Universitari
Joan XXIII, Tarragona (Olga Calavia), Consorci Sanitari
del Maresme, Mataro (Lourdes Garcıa), Hospital General
de Granollers (Maite Coll), Corporacio Sanitaria Parc
Taulı, Sabadell (Valentı Pineda), Hospital Universitari
Sant Joan, Reus (Neus Rius), Fundacio Althaia, Manresa
(Nuria Rovira), Hospital Son Espases, Mallorca (Joaquın
Due~nas) and Hospital Sant Joan de Deu, Esplugues
(Claudia Fortuny and Antoni Noguera-Julian).
Spain: CoRISPE-S and Madrid cohort: Marıa Jose Mel-
lado, Luis Escosa, Milagros Garcıa Hortelano and Talıa
Sainz (Hospital La Paz); Marıa Isabel Gonzalez-Tome,
Pablo Rojo and Daniel Blazquez (Hospital Doce de Octu-
bre, Madrid); Jose Tomas Ramos (Hospital Clınico San
Carlos, Madrid); Luis Prieto and Sara Guillen (Hospital de
Getafe); Marıa Luisa Navarro, Jesus Saavedra, Mar San-
tos, Mª Angeles Mu~noz, Beatriz Ruiz, Carolina Fernandez
Mc Phee, Santiago Jimenez de Ory and Susana Alvarez
(Hospital Gregorio Mara~non); Miguel Angel Roa (Hospital
de Mostoles); Jose Beceiro (Hospital Prıncipe de Asturias,
Alcala de Henares); Jorge Martınez (Hospital Ni~no Jesus,
Madrid); Katie Badillo (Hospital de Torrejon); Miren Api-
lanez (Hospital de Donostia, San Sebastian); Itziar Poche-
ville (Hospital de Cruces, Bilbao); Elisa Garrote (Hospital
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de Basurto, Bilbao); Elena Colino (Hospital Insular
Materno Infantil, Las Palmas de Gran Canaria); Jorge
Gomez Sirvent (Hospital Virgen de la Candelaria, Santa
Cruz de Tenerife); Monica Garzon and Vicente Roman
(Hospital de Lanzarote); Abian Montesdeoca and Mer-
cedes Mateo (Complejo Universitario de Canarias, La
Laguna-Tenerife), Marıa Jose Mu~noz and Raquel Angulo
(Hospital de Poniente, El Ejido); Olaf Neth and Lola
Falcon (Hospital Virgen del Rocio, Sevilla); Pedro Terol
(Hospital Virgen de la Macarena, Sevilla); Juan Luis San-
tos (Hospital Virgen de las Nieves, Granada); David Mor-
eno (Hospital Carlos Haya, Malaga); Francisco Lendınez
(Hospital de Torrecardenas, Almerıa); Ana Grande (Com-
plejo Hospitalario Universitario Infanta Cristina, Badajoz);
Francisco Jose Romero (Complejo Hospitalario de
Caceres); Carlos Perez (Hospital de Cabue~nes, Gijon);
Miguel Lillo (Hospital de Albacete); Bego~na Losada
(Hospital Virgen de la Salud, Toledo); Mercedes Herranz
(Hospital Virgen del Camino, Pamplona); Matilde Bustillo
and Carmelo Guerrero (Hospital Miguel Servet, Zaragoza);
Pilar Collado (Hospital Clınico Lozano Blesa, Zaragoza);
Jose Antonio Couceiro (Complejo Hospitalario de Pon-
tevedra); Amparo Perez, Ana Isabel Piqueras, Rafael
Breton and Inmaculada Segarra (Hospital La Fe, Valen-
cia); Cesar Gavilan (Hospital San Juan de Alicante); Enri-
que Jare~no (Hospital Clınico de Valencia); Elena
Montesinos (Hospital General de Valencia); Marta Dapena
(Hospital de Castellon); Cristina Alvarez (Hospital
Marques de Valdecilla, Santander); Ana Gloria Andres
(Hospital de Leon); Vıctor Marugan and Carlos Ochoa
(Hospital de Zamora); Santiago Alfayate and Ana Isabel
Menasalvas (Hospital Virgen de la Arrixaca, Murcia);
Elisa de Miguel (Complejo Hospitalario San Millan-San
Pedro, Logro~no) and Paediatric HIV-BioBank integrated
in the Spanish AIDS Research Network and collaborating
centres. Funding: this work has been partially funded by
the Fundacion para la Investigacion y Prevencion de
SIDA en Espa~na (FIPSE) (FIPSE 3608229/09, FIPSE
240800/09 and FIPSE 361910/10), Red Tematica de
Investigacion en SIDA (RED RIS) supported by Instituto
de Salud Carlos III (ISCIII) (RD12/0017/0035 and RD12/
0017/0037) project as part of the Plan R + D + I and
cofinanced by ISCIII–Subdireccion General de Evaluacion
and Fondo Europeo de Desarrollo Regional (FEDER),
Mutua Madrile~na 2012/0077, Gilead Fellowship 2013/
0071, FIS PI15/00694, CoRISpe (RED RIS RD06/0006/
0035 and RD06/0006/0021).
Sweden: Karolinska Institute and University Hospital,
Stockholm (Lars Naver, Sandra Soeria-Atmadja and Ven-
dela Hagas).
Switzerland: Members of the Swiss HIV Cohort Study
(SHCS) and the Swiss Mother and Child HIV Cohort
Study: Aebi-Popp K, Anagnostopoulos A, Asner S, Batte-
gay M, Baumann M, Bernasconi E, Bo¨ni J, Braun DL,
Bucher HC, Calmy A, Cavassini M, Ciuffi A, Duppenthaler
A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Fran-
cini K, Furrer H, Fux CA, Grawe C, Gu¨nthard HF (Presi-
dent of the SHCS), Haerry D (deputy of "Positive
Council"), Hasse B, Hirsch HH, Hoffmann M, Ho¨sli I,
Huber M, Kahlert CR (Chairman of the Mother & Child
Substudy), Kaiser L, Keiser O, Klimkait T, Kottanattu L,
Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Marti-
nez de Tejada B, Marzolini C, Metzner KJ, Mu¨ller N,
Nicca D, Paioni P, Pantaleo G, Perreau M, Polli Ch, Rauch
A (Chairman of the Scientific Board), Rudin C, Scherrer
AU (Head of Data Centre), Schmid P, Speck R, Sto¨ckle M
(Chairman of the Clinical and Laboratory Committee),
Tarr P, Thanh Lecompte M, Trkola A, Vernazza P, Wagner
N, Wandeler G, Weber R, Wyler CA, Yerly S.Funding:
This study has been financed within the framework of the
Swiss HIV Cohort Study, supported by the Swiss National
Science Foundation (grant #177499).
Thailand: Program for HIV Prevention & Treatment
(PHPT). Participating hospitals: Lamphun: Pornpun Wan-
narit; Phayao Provincial Hospital: Pornchai Techakunakorn;
Chiangrai Prachanukroh: Rawiwan Hansudewechakul; Chi-
ang Kham: Vanichaya Wanchaitanawong; Phan: Sookchai
Theansavettrakul; Mae Sai: Sirisak Nanta; Prapokklao: Chai-
wat Ngampiyaskul; Banglamung: Siriluk Phanomcheong;
Chonburi: Suchat Hongsiriwon; Rayong: Warit Karnchana-
mayul; Bhuddasothorn Chacheongsao: Ratchanee Kwan-
chaipanich; Nakornping: Suparat Kanjanavanit; Somdej
Prapinklao: Nareerat Kamonpakorn and Maneeratn Nan-
tarukchaikul; Bhumibol Adulyadej: Prapaisri Layangool and
Jutarat Mekmullica; Pranangklao: Paiboon Lucksanapisitkul
and Sudarat Watanayothin; Buddhachinaraj: Narong Lertpi-
enthum; Hat Yai: Boonyarat Warachit; Regional Health Pro-
motion Center 6, Khon Kaen: Sansanee Hanpinitsak; Nong
Khai: Sathit Potchalongsin; Samutsakhon: Pimpraphai Tha-
nasiri and Sawitree Krikajornkitti; Phaholpolphayuhasena:
Pornsawan Attavinijtrakarn; Kalasin: Sakulrat Srirojana;
Nakhonpathom: Suthunya Bunjongpak; Samutprakarn:
Achara Puangsombat; Mahasarakam: Sathaporn Na-Raj-
sima; Roi-et: Pornchai Ananpatharachai; Sanpatong: Nop-
padon Akarathum; Vachira Phuket: Weerasak Lawtongkum;
Chiangdao: Prapawan Kheunjan, Thitiporn Suriyaboon and
Airada Saipanya. Data management team: Kanchana Than-
in-at, Nirattiya Jaisieng, Rapeepan Suaysod, Sanuphong
Chailoet, Naritsara Naratee and Suttipong Kawilapat.
Ukraine: Paediatric HIV Cohort: T. Kaleeva, Y. Barysh-
nikova (Odessa Regional Centre for HIV/AIDS), S. Soloha
(Donetsk Regional Centre for HIV/AIDS), N. Bashkatova
(Mariupol AIDS Centre), I. Raus (Kiev City Centre for
HIV/AIDS), O. Glutshenko and Z. Ruban (Mykolaiv
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Regional Centre for HIV/AIDS), N. Prymak (Kryvyi Rih),
G. Kiseleva (Simferopol) and H. Bailey (UCL, London,
UK). Funding acknowledgement: PENTA Foundation.
UK & Ireland: Collaborative HIV Paediatric Study
(CHIPS): CHIPS is funded by the NHS (London Specialised
Commissioning Group) and has received additional sup-
port from Bristol-Myers Squibb, Boehringer Ingelheim,
GlaxoSmithKline, Roche, Abbott, and Gilead Sciences.
The MRC Clinical Trials Unit at UCL is supported by the
Medical Research Council (https://www.mrc.ac.uk) pro-
gramme number MC_UU_12023/26. CHIPS Steering Com-
mittee: Hermione Lyall, Karina Butler, Katja Doerholt,
Caroline Foster, Nigel Klein, Esse Menson, Andrew Rior-
dan, Delane Shingadia, Gareth Tudor-Williams, Pat Too-
key and Steve Welch. MRC Clinical Trials Unit: Intira
Jeannie Collins, Claire Cook, Donna Dobson, Keith Fair-
brother, Diana M. Gibb, Ali Judd, Lynda Harper, Fran-
cesca Parrott, Anna Tostevin and Nadine Van Looy.
Participating hospitals: Republic of Ireland: Our Lady’s
Children’s Hospital Crumlin, Dublin: K. Butler and A.
Walsh. UK: Birmingham Heartlands Hospital, Birming-
ham: S. Scott, Y. Vaughan and S. Welch; Blackpool Vic-
toria Hospital, Blackpool: N. Laycock; Bristol Royal
Hospital for Children, Bristol: J. Bernatoniene, A. Finn
and L. Hutchison; Calderdale Royal Hospital, Halifax: G.
Sharpe; Central Middlesex Hospital, London: A. Williams;
Chelsea and Westminster Hospital, London: E. G. H Lyall
and P. Seery; Coventry & Warwickshire University Hospi-
tal, Coventry: P. Lewis and K. Miles; Derbyshire Chil-
dren’s Hospital, Derby: B. Subramaniam; Derriford
Hospital, Plymouth: L. Hutchinson and P. Ward; Ealing
Hospital, Middlesex: K. Sloper; Eastbourne District Gen-
eral Hospital, Eastbourne: G. Gopal; Glasgow Royal
Hospital for Sick Children, Glasgow: C. Doherty, R. Hague
and V. Price; Great Ormond St Hospital for Children, Lon-
don: A. Bamford, H. Bundy, M. Clapson, J. Flynn, D. M.
Gibb, N. Klein, V. Novelli and D. Shingadia; Halliwell
Children’s Centre, Bolton: P. Ainsley-Walker; Harrogate
District Hospital, Harrogate: P. Tovey; Homerton Univer-
sity Hospital, London: D. Gurtin; Huddersfield Royal
Infirmary, Huddersfield: J. P. Garside; James Cook Hospi-
tal, Middlesbrough: A. Fall; John Radcliffe Hospital,
Oxford: D. Porter and S. Segal; King’s College Hospital,
London: C. Ball and S. Hawkins; Leeds General Infirmary,
Leeds: P. Chetcuti and M. Dowie; Leicester Royal Infir-
mary, Leicester: S. Bandi and A. McCabe; Luton and Dun-
stable Hospital, Luton: M. Eisenhut; Mayday University
Hospital, Croydon: J. Handforth; Milton Keynes General
Hospital, Milton Keynes: P. K. Roy; Newcastle General
Hospital, Newcastle: T. Flood and A. Pickering; Newham
General Hospital, London: S. Liebeschuetz; Norfolk &
Norwich Hospital, Norwich: C. Kavanagh; North
Manchester General Hospital, Manchester: C. Murphy, K.
Rowson and T. Tan; North Middlesex Hospital, London: J.
Daniels and Y. Lees; Northampton General Hospital,
Northampton: E. Kerr and F. Thompson; Northwick Park
Hospital, Middlesex; M. Le Provost and A. Williams; Not-
tingham City Hospital, Nottingham: L. Cliffe, A. Smyth
and S. Stafford; Queen Alexandra Hospital, Portsmouth:
A. Freeman; Raigmore Hospital, Inverness: T. Reddy;
Royal Alexandra Hospital, Brighton: K. Fidler; Royal Bel-
fast Hospital for Sick Children, Belfast: S. Christie; Royal
Berkshire Hospital, Reading: A. Gordon; Royal Children’s
Hospital, Aberdeen: D. Rogahn; Royal Cornwall Hospital,
Truro: S. Harris and L. Hutchinson; Royal Devon and
Exeter Hospital, Exeter: A. Collinson and L. Hutchinson;
Royal Edinburgh Hospital for Sick Children, Edinburgh:
L. Jones and B. Offerman; Royal Free Hospital, London:
V. Van Someren; Royal Liverpool Children’s Hospital,
Liverpool: C. Benson and A. Riordan; Royal London
Hospital, London: A. Riddell; Royal Preston Hospital, Pre-
ston: R. O’Connor; Salisbury District General Hospital,
Salisbury: N. Brown; Sheffield Children’s Hospital, Shef-
field: L. Ibberson and F. Shackley; Southampton General
Hospital, Southampton: S. N. Faust and J. Hancock; St
George’s Hospital, London: K. Doerholt, S. Donaghy, K.
Prime, M. Sharland and S. Storey; St Luke’s Hospital,
Bradford: S. Gorman; St Mary’s Hospital, London: E. G.
H. Lyall, C. Monrose, P. Seery, G. Tudor-Williams and S.
Walters; St Thomas’ Hospital (Evelina Children’s Hospi-
tal), London: R. Cross and E. Menson; Torbay Hospital,
Torquay: J. Broomhall and L. Hutchinson; University
Hospital Lewisham, London: D. Scott and J. Stroobant;
University Hospital of North Staffordshire, Stoke On
Trent: A. Bridgwood and P. McMaster; University Hospi-
tal of Wales, Cardiff: J. Evans and T. Gardiner; Wexham
Park, Slough: R. Jones; Whipps Cross Hospital, London:
K. Gardiner.
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Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. Flow chart of participants included in the
study.
Figure S2. Observed CD4% prior to first treatment inter-
ruption against predicted CD4% after 24 months on ART.
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Table S1. Multivariable models for CD4% in the
24 months after restart of ART following first treatment
interruption in children who initiated ART on cART.
Table S2. Multivariable associations between characteris-
tics and CD4% after restart of ART following first ever
30-day and first ever 3-month treatment interruption (ex-
cluding laboratory data).
Table S3. Multivariable associations between characteris-
tics and CD4% after restart of ART following first ever
30-day and first ever 90-day TI (including laboratory
data).
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